TW201111357A - Solid forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione and methods of making the same - Google Patents
Solid forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione and methods of making the same Download PDFInfo
- Publication number
- TW201111357A TW201111357A TW099131402A TW99131402A TW201111357A TW 201111357 A TW201111357 A TW 201111357A TW 099131402 A TW099131402 A TW 099131402A TW 99131402 A TW99131402 A TW 99131402A TW 201111357 A TW201111357 A TW 201111357A
- Authority
- TW
- Taiwan
- Prior art keywords
- amino
- dione
- dihydro
- iso
- piperidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Description
201111357 六、發明說明: 【發明所屬之技術領域】 本發明係關於一種新穎結晶形態或非晶形態之3-(4-胺 基-1-側氧基-1,3-二氫-異σ引ϋ朵-2-基)-α底σ定-2,6-二嗣及其製備 方法、包含該等新穎形態之醫藥組合物。 【先前技術】 眾所皆知’ 3-(4-胺基-1-側氧基-1,3-二鼠-異叫卜朵-2-基)_ 派咬-2,6-二S同或來那度胺(lenalidomide)對各式各樣疾病之 治療及預防是有用的,該些疾病包含但不限於發炎性疾 病、自體免疫疾病及癌症。 吾人已製得呈現獨特性質之結晶及非晶形態之3 - (4 -胺 基-1 -側氧基-1,3-二鼠-異°引α朵-2-基)-略σ定-2,6-二嗣。 【發明内容】 【實施方式】 結晶形態I之合成 形態I之3-(4-胺基-1-側氧基-1,3-二風-異°5丨鳴-2-基)-派交 -2,6-二酮之製備 一般而言,形態I可藉由於甲醇/水溶劑系統下進行蒸 發作用而製得,形態I亦可自熱水漿料(hot water slurry)系 統中之形態A來製得,形態A為無水形態,其揭露於美國 專利第7,465,800號中。以下呈現所有方法之具體實施例。 3 201111357 實施例1 : 將3-(4-胺基-1-側氧基-i,3-二氫-異吲哚基)_哌 -2,6-二酮(300 mg)及水溶液(3〇 mi)之混合物於6〇ΐ下加熱3 小時。過濾混合物並於40¾之減壓條件下乾燥濕濾餅&^ cake)約28小時,以XRD及ir分析該固體,經鑑定 i 為形態I。 ’八 實施例2 將3 - (4 -胺基-1 -側氧基_丨,3 ·二氫_異吲哚_ 2 _基)_哌 -2,6-二酮(約1.3 g)及甲醇(約260 ml)之溶液進料至5〇〇时 之套管反應器(jacket reactor),接著將該溶液加熱至6〇<t。 濃縮該溶液以移除大約2/3之甲醇,並且將水進料至該漿料 溶液内,接著進一步濃縮該混合物以移除甲醇。過濾所得 之漿料三並且於40°C之減壓條件下乾燥濕濾餅大約35小 時,接著對經乾燥之樣品進行XRPD、tga、DSC及紅外 線漫射(diffuse reflectance)分析。分析結果如第一圖至第四 圖所示。 非晶形態之3-(4-胺基-1·側氧基_ι,3·二氫-異吲哚_2_基)_旅 啶-2,6-二酮之製備 實施例1 : 將結晶形態的3-(4-胺基-1 ·側氧基-1,3-二氫-異吲哚_2_ 基)-哌啶-2,6-二酮(約300 mg)溶於60°C之甲醇(50 ml),以得 一澄清溶液,將該澄清溶液於減壓下進行濃縮以移除甲醇 而得到固體《以XRD及紅外線漫射分析對該固體物質進行 分析’經鑑定後’其為非晶形態。參看第五圖及第六A圖 至第六C圖。 201111357 【圖式簡單說明】 第一 A圖至第一 B圖係形態I特有的X射線粉末繞射 圖譜。 第二圖係形態I之差示掃描熱分析儀(differential scanning calorimetry)圖譜。 第三圖係形態I之熱重分析(thermogravimetric analysis) 圖譜。 第四A圖至第四B圖係形態I之紅外線漫射圖譜。 第五圖係非晶形態特有的X射線粉末繞射圖譜。 第六A圖至第六C圖係非晶形態之紅外線漫射圖譜。
Claims (1)
- 201111357 七、申請專利範圍: I 一種結晶形態之3-(4-胺基-1-側氧基·1,3-二氫·異, 基),略σ定_2,6-二酮,其係具有2Θ約為12·1±〇·2及 13·4±0·2、18.9±0.2、23_9±0.2 及 25.8±0_2 度之 X 射線粉 末繞射圖譜。 2_如申請專利範圍第1項所述之結晶形態之3-(4-胺基-ΐ_ 侧氧基-1,3-二氳-異,°朵-2-基)-娘咬-2,6-二酮,其具有係 與第一Α圖及第一Β圖所示之圖譜一致的χ射線粉末繞 射圖譜實質上。 3. 如申請專利範圍第1項所述之結晶形態之3-(4-胺基-ΐ_ 側氧基-1,3-二氫-異吲哚-2-基)-派咬_2,6-二酮,其具有峰 值約為1698、1662、1493、1350及1203波數之紅外線 漫射(diffuse-reflectance)圖譜。 4. 如申請專利範圍第1項所述之結晶形態之3-(4-胺基_ι_ 側氧基-I,3·二氫異°引°朵_2_基)-η底咬_2,6_二酮,其具有實 質上與第四A圖及第四B圖所示之圖譜一致之紅外線漫 射圖譜。 S · —種製備如申睛專利範圍第1項所述之結晶形態3 胺基·i,氧基二氮-異㈣2_基)_二;·;二(二 方法,其包含: (a)將3-(4-胺基-1-側氧基4,3-二氫_異吲哚_2_基)-哌 啶-2,6-二酮於水溶液中加熱; ⑻將結晶形態之3-(4_胺基-丨_側氡基_丨,3_二氫·異吲 哚-2·基)·哌啶_2,6_二酮自該水溶液中分離出;及 (c)將分離出之該結晶形態之3_(4_胺基_丨_側氧基 -1,3-二氫·異吲哚-2-基)·哌啶-2,6_二酮予以乾燥。 6. -種製備如中請專利範圍第i項所述之結晶形態之3普 胺基小側氧基-1,3-二氫異十朵_2_基)_派务2 6_二嗣的 201111357 方法,其包含: (a)將 3-(4-胗其-1_/日,丨 $ « , _(c)加入水,以產生第二溶液;-2-基)-哌啶_2,6-二酮分離出;及 a 1丨刀π汉1f醇移除,接著將結 態之3-(4-胺基側氧基_丨,3_二氫-異吲哚 (e)將分離出之該結晶形態之3·(4_胺基j •側氧基 -1,3-二氫-異吲哚_2_基)_哌啶_2,6•二酮予以乾燥。 7.種非曰Β形態之弘(4-胺基-1-側氧基_ι,3_二氫_異吲哚·2· 基)-娘咬-2,6-二酮。 8·如申请專利範圍第7項所述之非晶形態之3-(4-胺基_1_ 側氧基-1,3-一氣-異α弓卜朵_2_基)_派咬_2,6_二酮’其具有實 質上係與第五圖所示之圖譜一致的χ射線粉末繞射圖 譜。 9·如申請專利範圍第7項所述之非晶形態之3-(4-胺基-1-側氧基-1,3-一氫-異π弓卜朵-2-基)-α辰咬-2,6-二酮,其具有峰 值約為1708、1609、1493、1348及1206波數之紅外線 漫射圖譜。 10·如申請專利範圍第7項所述之非晶形態之3-(4-胺基-1-側氧基-1,3-二氮-異σ引α朵-2-基)-U底咬-2,6-二網,其具有實 夤上與第六Α圖及第六Β圖所示之圖譜一致之紅外線漫 射圖譜。 U.—種製備如申請專利範圍第7項所述之非結晶形態之 3-(4-胺基-1-側氧基_ι,3·二氫-異π弓| u朵-2-基)-α底咬_2,6-二 酮的方法,其包含: ⑻將3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌 201111357 •驷浴解於尹醇中. (b)ii 移? ’以得非日日日形態之3-(4-胺基-1-側 種醫筚二二,朵-2_基)如 …之結::態 終2,一 第,樂組合物’其包含-治療有效量之巾請專利範圍 o^j 〇n.之非結晶形態之3-(心胺基-1-側氧基-i,3-二氫_異 / 2-基)_派咬-2,6-二酮及一醫藥可接受之载體。 8
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24320409P | 2009-09-17 | 2009-09-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201111357A true TW201111357A (en) | 2011-04-01 |
TWI475014B TWI475014B (zh) | 2015-03-01 |
Family
ID=43731172
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW099131402A TWI475014B (zh) | 2009-09-17 | 2010-09-16 | 固體形態的3-(4-胺基-1-側氧基-1,3-二氫-異吲哚-2-基)-哌啶-2,6-二酮及其製造方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8420672B2 (zh) |
EP (1) | EP2477975B1 (zh) |
JP (1) | JP2013505234A (zh) |
KR (1) | KR20120068002A (zh) |
CN (1) | CN102639522A (zh) |
AR (1) | AR078395A1 (zh) |
AU (1) | AU2010296072B2 (zh) |
TW (1) | TWI475014B (zh) |
WO (1) | WO2011034504A1 (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
CN101696205B (zh) * | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
MX2013010360A (es) | 2011-03-11 | 2014-04-14 | Celgene Corp | Formas solidas sde 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-pi peridin-2,6-diona, y sus composiciones farmaceuticas y usos. |
US9540341B2 (en) * | 2011-07-19 | 2017-01-10 | Amplio Pharma, Llc | Crystalline forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
CN104016966A (zh) * | 2014-01-30 | 2014-09-03 | 上海创诺制药有限公司 | 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法 |
WO2015113314A1 (zh) * | 2014-01-30 | 2015-08-06 | 上海创诺制药有限公司 | 3-(4-氨基-1,3-二氢-1-氧代-2h-异吲哚-2-基)-2,6-哌啶二酮新晶型及其制备方法 |
CN112062751A (zh) * | 2017-08-04 | 2020-12-11 | 正大天晴药业集团股份有限公司 | 一种来那度胺的新结晶及其药物组合物 |
CN108191826A (zh) * | 2018-01-08 | 2018-06-22 | 浙江省医学科学院 | 一种来那度胺晶体及其制备方法 |
RU2723624C1 (ru) * | 2019-12-31 | 2020-06-16 | Общество с ограниченной ответственностью «АксельФарм» | Наноаморфная форма (rs)-3-(4-амино-1-оксо-1,3-дигидро-2н-изоиндол-2-ил)пиперидин-2,6-дион (варианты), способ её получения и применение для лечения иммунологических или онкологических заболеваний |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
UA83504C2 (en) * | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
WO2006028964A1 (en) * | 2004-09-03 | 2006-03-16 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
JP2011513497A (ja) * | 2008-03-11 | 2011-04-28 | ドクター・レディーズ・ラボラトリーズ・リミテッド | レナリドミドの調製 |
US20110060010A1 (en) * | 2008-03-13 | 2011-03-10 | Tianjin Hemay Bio-Tech Co., Ltd | Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof |
CN102272118A (zh) * | 2008-11-03 | 2011-12-07 | 基因里克斯(英国)有限公司 | 来那度胺的晶型及其制备方法 |
EP2355802A1 (de) | 2008-11-14 | 2011-08-17 | Ratiopharm GmbH | Intermediate und orale darreichungsformen enthaltend lenalidomid |
NZ595492A (en) * | 2009-03-02 | 2013-07-26 | Generics Uk Ltd | Improved Process for the Preparation of Lenalidomide |
DK2403822T3 (en) | 2009-03-03 | 2015-03-02 | Chr Hansen As | Use of DATEM in the production media for lactic acid bacteria |
WO2010129636A2 (en) * | 2009-05-08 | 2010-11-11 | Dr. Reddy's Laboratories Ltd. | Lenalidomide polymorph |
US20120220777A1 (en) * | 2009-09-16 | 2012-08-30 | Ranbaxy Laboratories Limited | Process for the preparation of a crystalline form of lenalidomide |
WO2011061611A1 (en) * | 2009-11-19 | 2011-05-26 | Ranbaxy Laboratories Limited | Process for the preparation of form b of lenalidomide |
CN101817813B (zh) * | 2010-01-15 | 2013-04-10 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮晶体ⅳ及其药用组合物 |
EP2545043B1 (en) * | 2010-03-08 | 2019-04-24 | Natco Pharma Limited | Anhydrous lenalidomide form-i |
-
2010
- 2010-09-16 TW TW099131402A patent/TWI475014B/zh not_active IP Right Cessation
- 2010-09-17 EP EP10817525.8A patent/EP2477975B1/en not_active Not-in-force
- 2010-09-17 US US12/885,065 patent/US8420672B2/en not_active Expired - Fee Related
- 2010-09-17 AU AU2010296072A patent/AU2010296072B2/en not_active Ceased
- 2010-09-17 KR KR1020127006464A patent/KR20120068002A/ko not_active Application Discontinuation
- 2010-09-17 AR ARP100103409A patent/AR078395A1/es unknown
- 2010-09-17 WO PCT/SG2010/000345 patent/WO2011034504A1/en active Application Filing
- 2010-09-17 CN CN201080041395XA patent/CN102639522A/zh active Pending
- 2010-09-17 JP JP2012529718A patent/JP2013505234A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2477975A1 (en) | 2012-07-25 |
US8420672B2 (en) | 2013-04-16 |
KR20120068002A (ko) | 2012-06-26 |
TWI475014B (zh) | 2015-03-01 |
AR078395A1 (es) | 2011-11-02 |
AU2010296072B2 (en) | 2014-03-27 |
WO2011034504A1 (en) | 2011-03-24 |
AU2010296072A1 (en) | 2012-03-22 |
JP2013505234A (ja) | 2013-02-14 |
EP2477975A4 (en) | 2013-03-13 |
CN102639522A (zh) | 2012-08-15 |
EP2477975B1 (en) | 2018-01-10 |
US20110065750A1 (en) | 2011-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW201111357A (en) | Solid forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2, 6-dione and methods of making the same | |
US10189837B2 (en) | Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt | |
RU2497820C2 (ru) | Кристаллические формы и две сольватные формы солей молочной кислоты 4-амино-5-фтор-3-[5-(4-метилпиперазин-1-ил)-1 - н-бензимидазол-2-ил]хинолин-2(1н)она | |
TWI273104B (en) | Novel fused imidazole derivative | |
KR20080056183A (ko) | 2-[[6-[(3r)-3-아미노-1-피페리디닐]-3,4-디히드로-3-메틸-2,4-디옥소-1(2h) -피리미디닐]메틸]-벤조니트릴의벤조에이트염의 폴리모르프 및 그 사용 방법 | |
TWI259081B (en) | Treatment of acute myeloid leukemia with indolinone compounds | |
CN1301154A (zh) | 酰胺衍生物和nociceptin拮抗剂 | |
JP6038150B2 (ja) | Nedd8活性化酵素阻害剤 | |
TW200811162A (en) | Inhibitors of C-FMS kinase | |
TW200306180A (en) | New compounds | |
CN110770242B (zh) | 作为vanin抑制剂的杂芳族化合物 | |
WO2012047871A1 (en) | Polymorphs of saxagliptin hydrochloride and processes for preparing them | |
CN107567445A (zh) | 可用作哺乳动物酪氨酸激酶ror1活性抑制剂的2‑苯基‑3h‑咪唑并[4,5‑b]吡啶衍生物 | |
US10155007B2 (en) | Synthesis method for improved tenofovir disoproxil fumarate using ion-exchange resin and method for preparing oral dissolving film form using the same | |
IL279579B (en) | Crystalline form of a compound to inhibit the activity of cdk4/6 and its use | |
TW201904955A (zh) | 可作為cgrp受體拮抗劑之3-甲基-吡咯啶-2,5-二酮衍生物 | |
JP2018520188A (ja) | 呼吸器合胞体ウイルス(rsv)感染症の処置のためのn−[(3−アミノ−3−オキセタニル)メチル]−2−(2,3−ジヒドロ−1,1−ジオキシド−1,4−ベンゾチアゼピン−4(5h)−イル)−6−メチル−4−キナゾリンアミンの結晶形 | |
CN102099338A (zh) | 用于治疗神经退行性疾病的杂环衍生物 | |
JP2020519685A (ja) | Cgrp受容体拮抗薬 | |
CN1726208A (zh) | E-2-甲氧基-n-( 3-{4-[3-甲基-4-( 6-甲基-吡啶-3-基氧基)-苯基氨基]-喹唑啉-6-基}-烯丙基)-乙酰胺的配合物、其制备方法和用途 | |
JP7369798B2 (ja) | Cdkキナーゼ阻害剤 | |
JP2009542738A (ja) | バニロイド−1受容体モジュレータとしてのビアリールカルボキシアリールアミド | |
TWI301889B (zh) | ||
IL280639B (en) | History of thiazoles and their pharmaceutically acceptable salts | |
WO2019001414A1 (zh) | 一种苯并二氮杂䓬化合物的固态形式及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |